Free Trial

Arrowhead Pharmaceuticals (ARWR) Stock Price, News & Analysis

+0.12 (+0.48%)
(As of 05/22/2024 ET)
Today's Range
50-Day Range
52-Week Range
634,249 shs
Average Volume
1.03 million shs
Market Capitalization
$3.12 billion
P/E Ratio
Dividend Yield
Price Target

Arrowhead Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.78 Rating Score
102.9% Upside
$51.00 Price Target
Short Interest
7.74% of Shares Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.58mentions of Arrowhead Pharmaceuticals in the last 14 days
Based on 16 Articles This Week
Insider Trading
Selling Shares
$1.45 M Sold Last Quarter
Proj. Earnings Growth
From ($3.05) to ($2.71) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.95 out of 5 stars

Medical Sector

190th out of 920 stocks

Pharmaceutical Preparations Industry

76th out of 422 stocks

ARWR stock logo

About Arrowhead Pharmaceuticals Stock (NASDAQ:ARWR)

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

ARWR Stock Price History

ARWR Stock News Headlines

Arrowhead Pharmaceuticals, Inc. (ARWR)
See More Headlines
Receive ARWR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arrowhead Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
9 Analysts


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$240.74 million
Book Value
$3.99 per share


Free Float
Market Cap
$3.12 billion
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Dr. Christopher R. Anzalone Ph.D. (Age 55)
    CEO, President & Director
    Comp: $1.6M
  • Mr. Kenneth A. MyszkowskiMr. Kenneth A. Myszkowski (Age 58)
    Chief Financial Officer
    Comp: $834.34k
  • Mr. Patrick O'Brien J.D. (Age 60)
    PharmD, COO, General Counsel & Secretary
    Comp: $835.14k
  • Dr. James C. Hamilton M.D. (Age 46)
    MBA, Chief of Discovery & Translational Medicine
    Comp: $762.14k
  • Dr. Mark M. Davis Ph.D.
    Founder and Founder & Director of Insert Therapeutics Inc & Calando
  • Dr. Vincent Anzalone CFA
    Head of Investor Relations & VP
  • Mr. Howard Lovy
    Director of Communications
  • Dr. Bruce D. Given M.D. (Age 70)
    Chief Medical Scientist
    Comp: $486.31k
  • Dr. Mark Seefeld (Age 70)
    Head of Toxicology & VP
  • Ms. Tracie  OliverMs. Tracie Oliver (Age 62)
    Chief Commercial Officer
    Comp: $449.58k

ARWR Stock Analysis - Frequently Asked Questions

Should I buy or sell Arrowhead Pharmaceuticals stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arrowhead Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ARWR shares.
View ARWR analyst ratings
or view top-rated stocks.

What is Arrowhead Pharmaceuticals' stock price target for 2024?

9 brokers have issued 1-year price objectives for Arrowhead Pharmaceuticals' stock. Their ARWR share price targets range from $27.00 to $90.00. On average, they predict the company's share price to reach $51.00 in the next twelve months. This suggests a possible upside of 102.9% from the stock's current price.
View analysts price targets for ARWR
or view top-rated stocks among Wall Street analysts.

How have ARWR shares performed in 2024?

Arrowhead Pharmaceuticals' stock was trading at $30.60 on January 1st, 2024. Since then, ARWR stock has decreased by 17.8% and is now trading at $25.14.
View the best growth stocks for 2024 here

When is Arrowhead Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 5th 2024.
View our ARWR earnings forecast

How were Arrowhead Pharmaceuticals' earnings last quarter?

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) issued its quarterly earnings data on Thursday, May, 9th. The biotechnology company reported ($1.02) earnings per share for the quarter, missing the consensus estimate of ($0.06) by $0.96. Arrowhead Pharmaceuticals had a negative net margin of 163.32% and a negative trailing twelve-month return on equity of 140.72%. Arrowhead Pharmaceuticals's revenue for the quarter was down 100.0% on a year-over-year basis. During the same period in the previous year, the company posted $0.45 EPS.

What other stocks do shareholders of Arrowhead Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arrowhead Pharmaceuticals investors own include Bellicum Pharmaceuticals (BLCM), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Alibaba Group (BABA), Alliance Resource Partners (ARLP), Bank of America (BAC), Tesla (TSLA), Salesforce (CRM) and Advanced Micro Devices (AMD).

Who are Arrowhead Pharmaceuticals' major shareholders?

Arrowhead Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (10.01%), Avoro Capital Advisors LLC (6.89%), Principal Financial Group Inc. (0.39%), Capital International Investors (0.39%), Retirement Systems of Alabama (0.28%) and Assenagon Asset Management S.A. (0.28%). Insiders that own company stock include Adeoye Y Olukotun, Backer Marianne De, Christopher Richard Anzalone, Douglas B Given, Douglas B Given, Hongbo Lu, James C Hamilton, James Hassard, Kenneth Allen Myszkowski, Martin Javier San, Patrick O'brien, Tracie Oliver, Victoria Vakiener and William D Waddill.
View institutional ownership trends

How do I buy shares of Arrowhead Pharmaceuticals?

Shares of ARWR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ARWR) was last updated on 5/23/2024 by Staff

From Our Partners